Search details
1.
Development of a new health-related quality of life measure for people with diabetes who experience hypoglycaemia: the Hypo-RESOLVE QoL.
Diabetologia
; 2024 May 22.
Article
in English
| MEDLINE | ID: mdl-38777868
2.
Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed-methods research protocol.
Diabet Med
; 40(3): e15007, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36398992
3.
Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: Results from a real-world nested case-control study.
Diabetes Obes Metab
; 24(7): 1235-1244, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35266273
4.
Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia Simulation.
Endocr Pract
; 28(5): 486-493, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35263661
5.
Conversations and Reactions Around Severe Hypoglycemia (CRASH) Study: Results From People With Diabetes and Caregivers in the United States.
Clin Diabetes
; 40(4): 477-488, 2022.
Article
in English
| MEDLINE | ID: mdl-36381307
6.
NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.
Endocr Pract
; 26(4): 407-415, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-32293921
7.
Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia.
Diabetes Metab Syndr Obes
; 15: 3601-3615, 2022.
Article
in English
| MEDLINE | ID: mdl-36439296
8.
Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances.
Clin Ther
; 41(10): 2073-2089.e6, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31526655
9.
Height Gain and Safety Outcomes in Growth Hormone-Treated Children with Idiopathic Short Stature: Experience from a Prospective Observational Study.
Horm Res Paediatr
; 91(4): 241-251, 2019.
Article
in English
| MEDLINE | ID: mdl-31185471
10.
Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program.
J Clin Endocrinol Metab
; 104(2): 379-389, 2019 02 01.
Article
in English
| MEDLINE | ID: mdl-30219920
11.
Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study.
CMAJ Open
; 6(3): E372-E383, 2018.
Article
in English
| MEDLINE | ID: mdl-30201821
12.
Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS).
Horm Res Paediatr
; 90(3): 169-180, 2018.
Article
in English
| MEDLINE | ID: mdl-30199857
13.
Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.
J Clin Endocrinol Metab
; 102(9): 3195-3205, 2017 09 01.
Article
in English
| MEDLINE | ID: mdl-28575299
14.
Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).
Clin Pediatr Endocrinol
; 26(4): 229-241, 2017.
Article
in English
| MEDLINE | ID: mdl-29026272
15.
Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial.
Horm Res Paediatr
; 87(1): 42-50, 2017.
Article
in English
| MEDLINE | ID: mdl-28002818
16.
Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population Databases.
Horm Res Paediatr
; 85(3): 198-206, 2016.
Article
in English
| MEDLINE | ID: mdl-26913923
17.
Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with isolated growth hormone deficiency due to organic causes.
Eur J Endocrinol
; 174(5): 669-79, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26888628
18.
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Eur J Endocrinol
; 172(6): 779-90, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25810462
19.
Radiological Features in Patients with Short Stature Homeobox-Containing (SHOX) Gene Deficiency and Turner Syndrome before and after 2 Years of GH Treatment.
Horm Res Paediatr
; 84(1): 14-25, 2015.
Article
in English
| MEDLINE | ID: mdl-25967354
20.
Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients.
J Clin Endocrinol Metab
; 89(10): 4857-62, 2004 Oct.
Article
in English
| MEDLINE | ID: mdl-15472176